GPER1 and MicroRNA: Two Players in Breast Cancer Progression
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Breast cancer is the main cause of morbidity and mortality in women worldwide. However, the molecular pathogenesis of breast cancer remains poorly defined due to its heterogeneity. Several studies have reported that G Protein-Coupled Estrogen Receptor 1 (GPER1) plays a crucial role in breast cancer progression, by binding to estrogens or synthetic agonists, like G-1, thus modulating genes involved in diverse biological events, such as cell proliferation, migration, apoptosis, and metastasis. In addition, it has been established that the dysregulation of short sequences of non-coding RNA, named microRNAs (miRNAs), is involved in various pathophysiological conditions, including breast cancer. Recent evidence has indicated that estrogens may regulate miRNA expression and therefore modulate the levels of their target genes, not only through the classical estrogen receptors (ERs), but also activating GPER1 signalling, hence suggesting an alternative molecular pathway involved in breast tumor progression. Here, the current knowledge about GPER1 and miRNA action in breast cancer is recapitulated, reporting recent evidence on the liaison of these two players in triggering breast tumorogenic effects. Elucidating the role of GPER1 and miRNAs in breast cancer might provide new tools for innovative approaches in anti-cancer therapy.
Tirado-Garibay A, Ruiz-Barcenas B, Rescala-Ponce de Leon J, Ochoa-Zarzosa A, Lopez-Meza J Int J Mol Sci. 2024; 25(16).
PMID: 39201674 PMC: 11354767. DOI: 10.3390/ijms25168988.
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.
da Silva F, Brandao D, Ferreira E, Siqueira R, Ferreira H, da Silva Filho A Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895937 PMC: 10610388. DOI: 10.3390/ph16101466.
Liu J, Niu Y, Zhang B, Sun Q, Li H, Bai L Int J Mol Sci. 2023; 24(18).
PMID: 37762356 PMC: 10531045. DOI: 10.3390/ijms241814055.
Overview of the therapeutic strategies for ER positive breast cancer.
Blakely B, Shin S, Jin K Biochem Pharmacol. 2023; 212:115552.
PMID: 37068524 PMC: 10394654. DOI: 10.1016/j.bcp.2023.115552.
Abbas M, Sayed I, Kamel Abdu-Allah A, Kalam A, Al-Sehemi A, Al-Hartomy O Noncoding RNA Res. 2022; 7(4):248-257.
PMID: 36247409 PMC: 9530401. DOI: 10.1016/j.ncrna.2022.09.003.